Michael R Whittaker
Overview
Explore the profile of Michael R Whittaker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahboob M, Subramaniam S, Tait J, Grace J, Elliott A, Floyd H, et al.
J Mater Chem B
. 2025 Jan;
13(8):2776-2795.
PMID: 39869058
Infections caused by fungal pathogens are a global health problem, and have created an urgent need for new antimicrobial strategies. This report details the synthesis of lipidated 2-vinyl-4,4-dimethyl-5-oxazolone (VDM) oligomers...
2.
Ediriweera G, Butcher N, Kothapalli A, Zhao J, Blanchfield J, Subasic C, et al.
Biomater Sci
. 2024 Apr;
12(11):2978-2992.
PMID: 38683548
Inhalable nanomedicines are increasingly being developed to optimise the pharmaceutical treatment of respiratory diseases. Large lipid-based nanosystems at the forefront of the inhalable nanomedicines development pipeline, though, have a number...
3.
Bester B, Koslowa K, Gronau A, Mietens A, Nowell C, Whittaker M, et al.
Br J Pharmacol
. 2024 Apr;
181(16):2869-2885.
PMID: 38676555
Background And Purpose: With increasing life expectancy, benign prostatic hyperplasia (BPH) consequently affects more ageing men, illustrating the urgent need for advancements in BPH therapy. One emerging possibility may be...
4.
Hussein M, Mahboob M, Tait J, Grace J, Montembault V, Fontaine L, et al.
mSystems
. 2024 Apr;
9(5):e0009324.
PMID: 38606960
The increasing resistance of clinically relevant microbes against current commercially available antimicrobials underpins the urgent need for alternative and novel treatment strategies. Cationic lipidated oligomers (CLOs) are innovative alternatives to...
5.
Abdallah M, Lin L, Styles I, Morsdorf A, Grace J, Gracia G, et al.
J Control Release
. 2024 Mar;
369:146-162.
PMID: 38513730
Delivery to peripheral lymphatics can be achieved following interstitial administration of nano-sized delivery systems (nanoparticles, liposomes, dendrimers etc) or molecules that hitchhike on endogenous nano-sized carriers (such as albumin). The...
6.
Ibrahim J, Dao N, Haque S, Phipps S, Whittaker M, Kaminskas L
J Pharm Sci
. 2024 Mar;
113(5):1395-1400.
PMID: 38460572
Liposomes are being developed as inhalable drug delivery systems, but concerns remain about their impact on the lungs. To better understand the impact of liposomes and their physicochemical properties on...
7.
Kaminskas L, Butcher N, Subasic C, Kothapalli A, Haque S, Grace J, et al.
Expert Opin Drug Deliv
. 2024 Jan;
21(1):151-167.
PMID: 38248870
Objectives: Nanomedicines are being actively developed as inhalable drug delivery systems. However, there is a distinct utility in developing smaller polymeric systems that can bind albumin in the lungs. We...
8.
Abdallah M, Lin L, Styles I, Morsdorf A, Grace J, Gracia G, et al.
Acta Biomater
. 2023 Dec;
174:191-205.
PMID: 38086497
Polymeric prodrugs have been applied to control the delivery of various types of therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to prolong systemic exposure. Here, we...
9.
Ibrahim J, Butcher N, Kothapalli A, Subasic C, Blanchfield J, Whittaker A, et al.
Expert Opin Drug Deliv
. 2023 Aug;
20(8):1145-1155.
PMID: 37535434
Objectives: Drug delivery systems typically show limited access to the lung interstitium and absorption after pulmonary delivery. The aim of this work was to undertake a proof-of-concept investigation into the...
10.
Khaw K, Whittaker M, Kuruppu S, Chan K, Gan S, Goh B
Front Pharmacol
. 2023 May;
14:1208546.
PMID: 37229254
No abstract available.